Cantargia & Truly Labs present anti-metastatic effect at AACR

The antibody is a novel mouse-specific surrogate of Cantargia’s proprietary antibody CAN04 currently investigated in clinical trials. The surrogate antibody counteracted metastases in an in vivo model of triple negative breast cancer. Mechanistically the antibody binds and blocks signaling through mouse IL1RAP, accumulates in the tumor tissue and recognizes IL1RAP expressing tumor infiltrating myeloid immune cells.

The poster can be viewed at Cantargia’s webpage: Anti-metastatic effect of IL1RAP blocking antibody at AACR